Research & Educational Use Only — Please Read
The peptides listed here are provided strictly for educational and research reference purposes only. This calculator is a mathematical dosing tool — it does not constitute medical advice, a treatment recommendation, or a protocol endorsement of any kind.
Many research peptides are not approved by the FDA for human use and are intended for laboratory and research contexts only. Always consult a licensed healthcare provider before making any health or supplementation decisions.
Baseline blood work is strongly recommended before beginning any peptide research protocol. Use the Blood Work guide in the Free Tools section for reference panels.
Lipolysis fragment of hGH. Sub-Q, fasted AM.
Syringe Fill
12% full
Draw Volume
0.120 mL
volume to draw
Syringe Units
12.0 units
U-100 (1 mL)
Concentration
2,500 mcg/mL
per mL
Shots Per Vial
16
~16-day supply
Sources & Disclaimer
[1] Goldstein AL, et al. (2012). Thymosin: Chemistry, Biology, and Clinical Applications. Ann NY Acad Sci. PMID: 22224837.
[2] Chang CH, et al. (2011). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression. J Orthop Res. PMID: 22664220.
[3] Sinha DK, et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues. Transl Androl Urol. PMID: 32055540.
[4] Mifflin MD, et al. (1990). A new predictive equation for resting energy expenditure. Am J Clin Nutr. PMID: 2305711.
[5] Vickers MH. (2009). Peptide analogues of growth hormone-releasing factor. Curr Opin Endocrinol. PMID: 19300092.
[6] Bhasin S, et al. (2010). Testosterone therapy in men with androgen deficiency syndromes. J Clin Endocrinol Metab. PMID: 20525905.
[7] Storer TW, et al. (2003). Testosterone dose-dependently increases maximal voluntary strength and leg power. J Clin Endocrinol Metab. PMID: 12679481.
[8] Hartgens F & Kuipers H. (2004). Effects of androgenic-anabolic steroids in athletes. Sports Med. PMID: 15248788.
[9] Kanayama G, et al. (2008). Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse. Drug Alcohol Depend. PMID: 18599224.
[10] Basaria S. (2010). Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. PMID: 20501690.
[11] Nieschlag E & Vorona E. (2015). Medical consequences of doping with anabolic androgenic steroids. Eur J Endocrinol. PMID: 26113524.
[12] Pope HG Jr, et al. (2014). Adverse health consequences of performance-enhancing drugs. Lancet. PMID: 24462202.
[13] Handelsman DJ. (2017). Androgen physiology, pharmacology, use and misuse. Endotext. PMID: 25905177.
[14] Shahidi NT. (2001). A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. PMID: 11589254.
[15] Hoberman JM & Yesalis CE. (1995). The history of synthetic testosterone. Sci Am. PMID: 7817189.
[16] Kicman AT. (2008). Pharmacology of anabolic steroids. Br J Pharmacol. PMID: 18500378.
[17] Lippi G & Guidi GC. (2008). Laboratory screening for doping with anabolic steroids. Clin Chim Acta. PMID: 18234171.
[18] Evans NA. (2004). Current concepts in anabolic-androgenic steroids. Am J Sports Med. PMID: 15262649.
For research and educational purposes only. Not medical advice. Anabolic-androgenic steroids are Schedule III controlled substances in the United States. JSW Coaching does not endorse or recommend the use of any controlled substance outside of a legally prescribed, medically supervised context. Consult a licensed physician before making any health decisions.